1-4 of 4 results for subject:"Glutarimer acetate"
Librarians' tools
- Search time
- 0.189 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:"Glutarimer acetate"
- We searched for
- subject_t:"Glutarimer acetate"
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
1st supplementary on same.
1st supplementary on same.
Asked by
Lord Addington
(Liberal Democrat)
Oral questions - 1st Supplementary
Status
Answered
Answered on
7 March 2001
Subjects
Cost effectiveness; Health services; Drugs; Medical treatments; Multiple sclerosis; Social services; National Institute for Clinical Excellence; Interferon beta; Glutarimer acetate
Date
7 March 2001
Reference
623 c202
Chamber / Committee
House of Lords chamber
House
House of Lords
Answered by
Lord Hunt of Kings Heath
(Labour)
Asked by
Lord Addington
(Liberal Democrat)
Type
Oral answers to questions
Whether the National Institute for Clinical Excellence (NICE), in assessing the cost-effectiveness of disease-modifying drugs in multiple sclerosis, will take into account all relevant cost savings to health and social services and the social security system.
Subjects
Cost effectiveness; Health services; Drugs; Medical treatments; Multiple sclerosis; Social services; National Institute for Clinical Excellence; Interferon beta; Glutarimer acetate
Date
7 March 2001
Reference
623 c202
Chamber / Committee
House of Lords chamber
House
House of Lords
Answered by
Lord Hunt of Kings Heath
(Labour)
Type
Oral answers to questions
Subjects
Cost effectiveness; Health services; Drugs; Medical treatments; Multiple sclerosis; Social services; National Institute for Clinical Excellence; Interferon beta; Glutarimer acetate
Date
7 March 2001
Reference
623 c202
Chamber / Committee
House of Lords chamber
House
House of Lords
Whether the National Institute for Clinical Excellence (NICE), in assessing the cost-effectiveness of disease-modifying drugs in multiple sclerosis, will take into account all relevant cost savings to health and social services and the social security system.
Whether the National Institute for Clinical Excellence (NICE), in assessing the cost-effectiveness of disease-modifying drugs in multiple sclerosis, will take into account all relevant cost savings to health and social services and the social security system.
Asked by
Lord Addington
(Liberal Democrat)
Answered by
Lord Hunt of Kings Heath
(Labour)
Oral questions - Lead
Status
Answered
For answer on
7 March 2001
Answered on
7 March 2001
Subjects
Cost effectiveness; Health services; Drugs; Medical treatments; Multiple sclerosis; Social services; National Institute for Clinical Excellence; Interferon beta; Glutarimer acetate
Date
7 March 2001
Reference
623 c202
Chamber / Committee
House of Lords chamber
House
House of Lords